Recently, ibrutinib19,20, a first-in-class Bruton’s tyrosine kinase (BTK) inhibitor and venetoclax21,22, a selective BCL2 inhibitor have been approved for CLL treatment. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.